Spots Global Cancer Trial Database for A Study of ZN-c3 in Patients With Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ZN-c3 in Patients With Ovarian Cancer
Official Title: A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer
Study ID: NCT04516447
Study Description
Brief Summary: This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Site 0264, Aurora, Colorado, United States
Site 0104, Boston, Massachusetts, United States
Site 0111, Saint Louis, Missouri, United States
Site 0173, New York, New York, United States
Site 0259, Durham, North Carolina, United States
Site 0191, Providence, Rhode Island, United States
Site 0196, Nashville, Tennessee, United States
Site 0103, Houston, Texas, United States
Site 2707, South Brisbane, Queensland, Australia
Site 2708, Sunshine Coast, Queensland, Australia
Site 2709, Adelaide, South Australia, Australia
Site 2706, Melbourne, Victoria, Australia
Site 2705, Nedlands, Western Australia, Australia
Site 1001, Banja Luka, , Bosnia and Herzegovina
Site 1002, Sarajevo, , Bosnia and Herzegovina
Site 1003, Tuzla, , Bosnia and Herzegovina
Site 1202, Panagyurishte, , Bulgaria
Site 1201, Sofia, , Bulgaria
Site 1401, Tbilisi, , Georgia
Site 2901, Busan, , Korea, Republic of
Site 2903, Seoul, , Korea, Republic of
Site 2904, Seoul, , Korea, Republic of
Site 1902, Belgrade, , Serbia
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
